Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma - Trial NCT06262516
Access comprehensive clinical trial information for NCT06262516 through Pure Global AI's free database. This phase not specified trial is sponsored by Case Comprehensive Cancer Center and is currently Not yet recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 94 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Case Comprehensive Cancer Center
Timeline & Enrollment
N/A
Jul 01, 2024
Jan 01, 2029
Primary Outcome
Recurrence-free survival
Summary
The goal of this study is to conduct the first randomized-controlled trial to determine the
 oncologic efficacy of lymph node dissection in participants with upper tract urothelial cell
 carcinoma. The main questions it aims to answer are:
 
 - To determine oncologic outcomes, specifically 2-year recurrence-free survival
 
 - To determine other oncologic outcomes including treatment-free, cancer-specific and
 overall survival
 
 - To determine time to recurrence and recurrence patterns
 
 - To determine use of adjuvant therapies
 
 - To determine perioperative complications
 
 Participants will undergo nephroureterectomy with or without lymph node dissection.
 Researchers will compare these two groups to determine the oncologic efficacy of performing
 lymph node dissection.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06262516
Non-Device Trial